Method of progesterone delivery and affect thereof
US5543150A · kind A · utility
104Cited by
1References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 15, 1993 |
| Grant date | Aug 6, 1996 |
| Priority date | — |
| Expiry date | Sep 15, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P15/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention teaches that relatively low levels of serum progesterone, 1 to 6 ng/ml, may be used to prevent endometrial cancer. The vaginal delivery of progesterone using a cross-linked polycarboxylic polymer produces this low serum progesterone level while also providing the full secretory transformation of the endometrium, indicating the efficacy of the progesterone. Such low levels of serum progesterone will decrease the risk of breast cancer experienced by women undergoing hormone replacement therapy ("HRT") and minimize the potential of other undesirable progesterone associated side effects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.